Hong Ellen S, Wang Sabrina Z, Ponti András K, Hajdari Nicole, Lee Juyeun, Mulkearns-Hubert Erin E, Volovetz Josephine, Kay Kristen E, Lathia Justin D, Dhawan Andrew
Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Medical Scientist Training Program (MSTP), School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Neurooncol Adv. 2024 Oct 30;6(1):vdae183. doi: 10.1093/noajnl/vdae183. eCollection 2024 Jan-Dec.
Biological sex is an important risk factor for glioblastoma (GBM), with males having a higher incidence and poorer prognosis. The mechanisms for this sex bias are thought to be both tumor intrinsic and tumor extrinsic. MicroRNAs (miRNAs), key posttranscriptional regulators of gene expression, have been previously linked to sex differences in various cell types and diseases, but their role in the sex bias of GBM remains unknown.
We leveraged previously published paired miRNA and mRNA sequencing of 39 GBM patients (22 male, 17 female) to identify sex-biased miRNAs. We further interrogated a separate single-cell RNA-sequencing dataset of 110 GBM patients to examine whether differences in miRNA target gene expression were tumor cell-intrinsic or tumor cell extrinsic. Results were validated in a panel of patient-derived cell models.
We identified 10 sex-biased miRNAs ( .1), of which 3 were more highly expressed in males and 7 more highly expressed in females. Of these, miR-644a was higher in females, and increased expression of miR-644a target genes was significantly associated with decreased overall survival (HR 1.3, = .02). Furthermore, analysis of an independent single-cell RNA-sequencing dataset confirmed sex-specific expression of miR-644a target genes in tumor cells ( < 10). Among patient-derived models, miR-644a was expressed a median of 4.8-fold higher in females compared to males.
Our findings implicate miR-644a as a candidate tumor cell-intrinsic regulator of sex-biased gene expression in GBM.
生物性别是胶质母细胞瘤(GBM)的一个重要风险因素,男性发病率更高且预后更差。这种性别差异的机制被认为既有肿瘤内在因素,也有肿瘤外在因素。微小RNA(miRNA)是基因表达的关键转录后调节因子,此前已与多种细胞类型和疾病中的性别差异相关,但它们在GBM性别差异中的作用仍不清楚。
我们利用先前发表的39例GBM患者(22例男性,17例女性)的配对miRNA和mRNA测序来鉴定性别偏向性miRNA。我们进一步研究了一个单独的110例GBM患者的单细胞RNA测序数据集,以检查miRNA靶基因表达的差异是肿瘤细胞内在的还是肿瘤细胞外在的。结果在一组患者来源的细胞模型中得到验证。
我们鉴定出10种性别偏向性miRNA(P<0.1),其中3种在男性中表达更高,7种在女性中表达更高。其中,miR-644a在女性中更高,miR-644a靶基因表达的增加与总生存期降低显著相关(HR 1.3,P=0.02)。此外,对一个独立的单细胞RNA测序数据集的分析证实了miR-644a靶基因在肿瘤细胞中的性别特异性表达(P<0.01)。在患者来源的模型中,与男性相比,miR-644a在女性中的表达中位数高4.8倍。
我们的研究结果表明,miR-644a是GBM中性别偏向性基因表达的候选肿瘤细胞内在调节因子。